Establishment of a hTfR mAb-functionalized HPPS theranostic nanoplatform

Abstract

Rational: Many efforts have been made to develop ligand-directed nanotheranostics in cancer management which could afford both therapeutic and diagnostic functions as well as tumor-tailored targeting. Theranostic nanoplatform targeting transferrin receptor (TfR) is an effective system for favorable delivery of diagnostic and therapeutic agents to malignancy site. Methods: To enable amalgamation of therapy and diagnosis to many TfR + tumor, hTfR (human TfR) monoclonal antibody (mAb)-functionalized HPPS nanoparticle (HPPS-mAb) was prepared with hTfR mAb on the shell and with fluorophore DiR-BOA in the core. The targeting specificity was investigated in vitro by immunostaining and in vivo using a double-tumor-engrafted mouse model. HPPS-mAb/siRNA effect on HepG2 cells was determined by RT-PCR and western blot. Results: HPPS-mAb could specifically target cancer cells through TfR and achieve tumor accumulation at an early valuable time node, thus efficiently delivering therapeutic survivin siRNA into TfR + HepG2 cells and mediating cell apoptosis. DiR-BOA can act as an imaging tool to diagnose cancer. Conclusions: Our studies provide a promising TfR mAb-directed theranostic nanoplatform candidate in tumor molecular imaging and in TfR targeted tumor therapy.

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

“…They demonstrated that drug entrapped HPPS based nanomedicines adapted with explicit ligands could muddle to receptors on the surface of tumor cells, resulting in the accretion of nanomedicines on the exterior surface of targeted cells [75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90]. It was concluded that developed HPPS based nanomedicine holds the potential to strengthen targeting to tumor cells and attains favored recognition by specific antibodies in a complex biological setting [91]. Such intricately woven novel research concept needs to be brought forth and encouraged thus that these kinds of potential research perceptions can be multiplied.…”

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies

“…Our preceding researches also revealed that the therapeutic strategies around TfR enhanced the antitumor effects ( 23 – 25 ). And anti-TfR mAb connected to functionalized HPPS nanoparticle enabled amalgamation of therapy and diagnosis to TfR + tumors ( 26 ). These optimized antibodies exhibited secure and efficacious anti-tumor activity and proved TfR was a worthwhile pharmaceutical target for the development of tumor therapy.…”